At a glance
- GLP-1 agonists suppress appetite by slowing gastric emptying and acting on satiety centers
- Semaglutide produced 14.9% weight loss in STEP-1 (Wilding 2021)
- Tirzepatide reached about 22.5% in SURMOUNT-1; retatrutide up to 24.2% in Phase 2
- Most OTC appetite suppressants lack comparable trial evidence
- Prescription GLP-1s require a telehealth or clinic pathway
Search best appetite suppressant and you get two very different answers: a shelf of over-the-counter pills with thin evidence, and the prescription GLP-1 drugs that actually reset hunger. The gap between those two groups is the whole story.
What appetite suppression actually means
Hunger is a hormone signal, not a willpower setting. The compounds that reliably reduce it do so by acting on the gut-brain axis: slowing how fast the stomach empties and signaling satiety centers in the brain. That is the mechanism behind the GLP-1 class, and it is why these drugs produce appetite reduction that over-the-counter options never matched.
The GLP-1 class: the actual best-in-class
Three drugs anchor the category, in ascending order of effect:
| Drug | Class | Trial result |
|---|---|---|
| Semaglutide | GLP-1 | 14.9% weight loss (STEP-1) |
| Tirzepatide | GIP/GLP-1 | about 22.5% (SURMOUNT-1) |
| Retatrutide | GLP-1/GIP/glucagon | up to 24.2% (Phase 2) |
Semaglutide 2.4mg produced 14.9% mean weight loss over 68 weeks (Wilding et al., NEJM 2021). Tirzepatide reached roughly 22.5% at the top dose (Jastreboff et al., NEJM 2022), and retatrutide hit up to 24.2% at 48 weeks in its Phase 2 trial (Jastreboff et al., NEJM 2023). Those are appetite-driven results: the weight comes off because people eat less without fighting it.
Where the OTC options fall short
Fiber, caffeine, and various botanical appetite suppressants have modest or inconsistent evidence, and none approach the effect size of a GLP-1. They are not useless for everyone, but they are not in the same category, and marketing that implies otherwise is the main trap in this search.
How to actually access the effective ones
GLP-1 drugs are prescription-only, which means a telehealth or clinic pathway. Compounded semaglutide and tirzepatide are the affordable route: compare current options on our cheapest GLP-1 guide. The research compounds behind them are on the retatrutide, tirzepatide, and cagrilintide pages (cagrilintide is an amylin analogue studied as a satiety partner), with protocols on the retatrutide dosage chart. For the full fat-loss framework, see our best peptides for fat loss guide.
Bottom line: The best appetite suppressants are the GLP-1 and multi-agonist drugs, full stop. They have the trial data; the OTC shelf does not. The only real question is which access pathway fits your budget.
This article is for research and educational purposes only. It is not medical advice, and GLP-1 medications are prescription drugs. Consult a licensed clinician before starting any weight-loss treatment.
